Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

January 31, 2014

Conditions
HIV Infection
Interventions
DRUG

Panobinostat

20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART

Trial Locations (1)

8200

Department of Infectious Diseases, Aarhus University Hospital, Aarhus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Monash University

OTHER

collaborator

University of Sydney

OTHER

collaborator

Novartis

INDUSTRY

collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER